[SMLE] RBD design increases the functional antibody titers elicited by SARS-CoV-2 spike vaccination

Répondre
Avatar du membre

Auteur du sujet
RSS-Bot
Ami(e) de Diamant
Ami(e) de Diamant
Messages : 6500
Enregistré le : 31 mai 2020 09:57
6
Zodiaque :
Âge : 22
Contact :
    unknown unknown

[SMLE] RBD design increases the functional antibody titers elicited by SARS-CoV-2 spike vaccination

Message par RSS-Bot »


Antiviral Res. 2024 Aug;228:105937. doi: 10.1016/j.antiviral.2024.105937. Epub 2024 Jun 18.

ABSTRACT

Most COVID-19 vaccines contain the SARS-CoV-2 spike protein as an antigen, but they lose efficacy as neutralizing antibody titers wane and escape variants emerge. Modifying the spike antigen to increase neutralizing antibody titers would help counteract this decrease in titer. We previously used a structure-based computational design method to identify nine amino acid changes in the receptor-binding domain (RBD) of spike that stabilize the RBD and increase the neutralizing antibody titers elicited by vaccination. Here, we introduce those enhancing amino acid changes into a full-length spike (FL-S-2P) ectodomain representative of most approved vaccine antigens. These amino acid changes can be incorporated into the FL-S-2P protein without negatively effecting expression or stability. Furthermore, the amino acid changes improved functional antibody titers in both mice and monkeys following vaccination. These amino acid changes could increase the duration of protection conferred by most COVID-19 vaccines.

PMID:38901738 | PMC:PMC11250568 | DOI:10.1016/j.antiviral.2024.105937


Source: https://pubmed.ncbi.nlm.nih.gov/3890173 ... t9+e462414
Si vous appréciez notre travail, merci de nous soutenir un petit don en cliquant ICI

Pour obtenir la traduction en français,
cliquez sur le bouton situé dans la barre des menus en haut de cette page 

Image


Pour les donateurs, si cet article vous intéresse, nous pouvons faire l’acquisition d'un tiré-à-part.
Merci d'en faire la demande sur [email protected]


Bonne lecture...
Répondre

Retourner vers « Syndrome Myasthénique de Lambert-Eaton - SMLE »